ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap
Article 2016 en
Authors
HA
Hans‐Joachim Anders
BR
Brad H. Rovin
DJ
David Jayne
Abstract
1 min read
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational
Veerle P. Persy, Giuseppe Remuzzi, Norberto Perico, Mohammed Benghanem Gharbi, Dwomoa Adu, Vivekanand Jha, Adib Rizvi, Mohamed Ben Ammar, S Fongoro, Marc E. De Broe
Kate Stevens, Eleni Frangou, Jae Il Shin, Hans‐Joachim Anders, Annette Bruchfeld, Ulf Schönermarck, Thomas Häuser, Kerstin Westman, Gema Fernández‐Juárez, Jürgen Floege, Dimitrios Goumenos, Kültiğin Türkmen, Cees van Kooten, Stephen P. McAdoo, Vladimı́r Tesař, Mårten Segelmark, Duvuru Geetha, David Jayne, Andreas Kronbichler
Marina Vivarelli, Jonathan Barratt, Laurence H. Beck, Fádi Fakhouri, Daniel P. Gale, Elena Goicoechea de Jorge, Marta Mosca, Marina Noris, Matthew C. Pickering, Katalin Suszták, Joshua M. Thurman, Michael Cheung, Jennifer King, Michel Jadoul, Wolfgang C. Winkelmayer, Richard J. Smith, Federico Alberici, Luca Antonucci, Tadej Avčin, Arvind Bagga, Ingeborg M. Bajema, Miquel Blasco, Sophie Chauvet,
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.